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ABSTRACT 
Adolescence is the rapid growing period when mainly the physical changes are important. 95% 
girls attain menarche at the age group of 10 to 16 yrs, the peak being 13yrs. Among them, not 
less than 50% of female are said to experience some discomfort or pain in relation to 
menstruation. Kashtartava is a symptom mentioned in various Yoni vyapads, Vata being the main 
causative factor for this condition, which is commonly compared with dysmenorrhoea by 
cotemporary science. Conventional treatment of primary dysmenorrhoea consists of non-
steroidal and anti-inflammatory drugs, hormonal therapy which causes unwanted side effects. 
Hence Rutukari Vati which is mentioned in Bheshaja Samhita for Kashtartava having the 
properties like, Vedanashamaka, Arthavajanana have been selected for the planned study.  
Design of Study: A Single blind comparative clinical study of two groups, trial and control, 
consisting of 15 subjects in each with pre-test and post-test design. Group A was given 
Rutukarivati and Group B was given Kumaryasava 25ml twice daily after food. Result: 
Rutukarivati contains most of the drugs with Tiktha and Katu rasa, Usnaveerya property and 
Vatakaphahara property; it is effective in controlling pain and regularizing the cycle. On 
comparison of overall effect of both groups has more significant result but percentage wise 
group A is more effective than group B. Mild increase in amount of bleeding was noted in 
patients in group A. It may be because of most of the ingredients in Rutukarivati are 
Artavajanana and Apanavatashaman. 
KEYWORDS: Kashtartava, Rutukari Vati, Kumaryasava, Primary dysmenorrhoea. 
INTRODUCTION 
Every month majority of women experience 
various symptoms attributed to their menstrual 
cycle, dysmenorrhoea being the most common 
among them.  
Dysmenorrhoea is defined as painful 
menstruation of sufficient magnitude so as to 
incapacitate day to day activities. It is usually primary 
and is associated with normal ovulatory cycles and 
with no pelvic pathology. 50% of menstruating 
women suffers from primary dysmenorrhoea out of 
which 10% are in capacitated for 1 to 3 days each 
month.  
 Pain is body’s most important alarm 
symptom, it draws attention to the fact something is 
at fault. Total absence of pain is also as disastrous as 
un controlled severe pain. However, uncontrolled 
pain is the single most common reason for people 
seek medical advice. 
The word “pain” is derived from the Latin 
counterpart “Poena” meaning penalty punishment or 
torment-rightly so as pain is the single most 
important symptom that brings patient to the 
emergency. 
Kashtartava[1] is symptom mentioned in 
various Yoni vyapads, vata being the main causative 
factor for this condition. As it is painful menstruation, 
it is commonly compared with dysmenorrhoea of 
contemporary science. 
It is the commonest of all gynaecological 
complaints. The menstrual blood flow is mainly 
under the control of Apana Vayu.[2] Vitiated 
Vatadosha is the main causative factor of 
Kashtartava. 
Today’s stressful modern life style, food 
habits, frequent interventions of female genital tract 
affects the uterine environment, which leads to 
higher incidence of dysmenorrhoea. 
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All the four factors Rutu (fertile period), 
Kshetra (female genital organ or whole body), Ambu 
(Ahara rasa), and Beeja (sperm and ovum) are 
affected indirectly by Kashtartava.  
The incidence of dysmenorrhoea is affected 
by social status, occupation and age, so groups of 
school girls, college students, factory workers and 
women members of the armed forces each provide 
different statistics. 
Conventional treatment of primary 
dysmenorrhoea consists of non-steroidal and anti-
inflammatory drugs, hormonal therapy which causes 
unwanted side effects. 
Ayurvedic herbo-mineral, non-hormonal, 
non-toxic preparations are proved effective in 
dysmenorrhoea.  
In this context, a single blind randomized 
clinical study is designed to prove the efficacy of trial 
drugs Rutukarivati in Kashtartav.[3] The Yoga 
Rutukarivati has been selected for the study because 
of their Vedanashamaka, Arthavajanaka as well as 
Vatapittaharaka properties.  
As Rutukarivati mentioned in Bheshaja 
Samhita is clinically found effective and scientifically 
not proved. The present study shows that 
RutukariVati has a significant effect on the 
Kashtartava. 
Kshatartava 
 Almost all Acharyas have described regarding 
this symptom but all references are scattered in 
description of different Yonivyapads. 
 Samhita's Symptoms References 
Caraka Samhita Saruk Vatala Yoni Vyapad (Cha. Chi. 30/10-11) 
Sa. Arti Paripluta and Maha Yoni Vyapad (Cha. Chi. 30/23-24, 36) 
Rajah Krichchhra Udavarta Yoni Vyapad (Cha. Chi. 30/25-26) 
Sushrutha Samhita Rajah Krichchhra Udavarta Yoni Vyapad (Su. U. 38/9-11) 
Vedana Vataja Artavadushti (Su. Sha. 2/4) 
Ashtanga Sangraha & 
Ashtanga Hridya 
Rajah Krichchhra Udavarta Yoni Vyapad (A. S. U. 38/36, A. H. U. 33/33-34) 
Sa- Rujam Vataja Artavadushti (A. S. Sha. 1/24, A. H. Sha. 1/10) 
HaritaSamhita Saruja Vataja Artavadushti ( H. S. tri. 48/13) 
Madhava Nidana, 
Bhavprakasha and 
Yoga Ratnakara 
Rajah Krichchhra Udavarta Yoni Vyapad (Ma. Ni. 62/2, Bha.Pra.Chi. 70/67) 
OBJECTIVES OF THE STUDY 
1. Conceptual study of Kashtartva. 
2. Clinical study of Rutukarivati and Kumaryasava in 
Kashatartva 
3. To compare the effect of Rutukari Vati and 
Kumaryasava in treatment of Kashatartva. 
Rutukarivati ingredients[4] 
Shunti, Samudraphena, Saindavalavana, 
Haridra, Hingu, Bola, Trivrit, Indravaruni, Tankana, 
Yavakshara, Sarjkshara, Kumari and Chitraka. 
Properties of the Drugs 
 Shunthia[5] has Vatanulomaka and Shoolapra 
shamana property. 
 It contains Gingerols and diarylhepatanoids 
which act as potent inhibitor of prostaglandin 
biosynthesis enzyme (PG synthetase). It contains 
saponins, which cause estrogenic activity by 
influencing oestrogen metabolism through 
enzyme pathways that influence hypothalamic 
receptors. And also has anti-emetic and anti- 
diarrhoeal property. (Kiuchi – 1992).[6] 
 Hingu[7] has Vatanulomana property which helps 
in normalizing the function of Apanavata, anti-
flatulent and digestive properties and 
counteracts spasmodic disorders. 
 Hingu may probably excite the secretion of 
progesterone hormone. 
 Kumari[8] contains beeta-sitosterol and has the 
anti prostaglandin activity. 
 Indravaruni[9] has a Kaphapittahara, recana. 
Garbhapataka properties. 
 Samudraphena, Yavakshara, Svarjakshara having 
Vatashamak, Deepana, Pachana properties.[10,11,12] 
 Haridra has a Kaphavatahara and Lekhana 
properties, which helps in Vedanshamana and 
Arthavajanana having the antiseptic 
properties.[13] 
 Bola has a Raktadoshaghna, Garbhashaya 
visshudhikrit properties.[14] 
MATERIALS AND METHOD 
The purpose of the clinical trial is primarily to 
establish the efficacy and demonstrate freedom from 
unwanted side effects in human. Appropriate 
medicine plays a paramount role in the success of 
treatment as it is a main factor lying with the 
management of a disease. In other words there is 
direct proportional relationship between the success 
of treatment and the genuineness of the medicine. 
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Source of Data 
a) Literary Source: All Ayurvedic classical, modern 
medical literatures, journals, website about the 
disease and drugs were referred and studied. 
b) Sample source: Patients attending the OPD of 
Prasoothitantra and Streeroga, Alva’s Ayurveda 
medical college and hospital, Moodbidri and other 
available sources were taken for the study. 
Method of collection of data 
30 patients according to inclusion and 
exclusion criteria, diagnosed as Kashtartva were 
selected from out-patient department of Alva’s 
Ayurveda Hospital, Moodbidri and other sources and 
were subjected to clinical study. 
A single blind clinical comparative study of two 
groups, consisting of 15 patients each with a pre-test 
and post-test design. 
 The selected 15 patients in group A were 
administered with Rutukari vati.  
 The selected 15 patients in group B were 
administered with Kumaryasava. 
 The duration of treatment for both group A and 
group B was 2months. A separate case proforma 
was prepared with history taking physical signs, 
symptoms USG findings and lab investigations as 
mentioned by allied sciences.  
 The parameters of signs, symptoms and 
investigations were scored on the basis of 
standard method and analysed statistically. 
Inclusion Criteria 
1. Patients coming with chief complaint of painful 
menstruation. 
2. Age group between 14 to 25 years. 
3. Patients with scanty menstruation or average 
amount of menses along with associated symptoms. 
Exclusion Criteria 
1. Patient with chronic illness 
2. Patient with intrauterine devices 
3. Menorrhagia 
4. Any uterine pathology– fibroid, adenomyosis, 
endometriosis 
5. Congenital anomalies leading to dysmenorrhoea. 
Investigations 
Hb%, USG etc., if necessary 
Intervention 
Group A 
Rutukarivati: 250 mg (2ratti) in tablet form  
Time of administration: 1 BD before food orally.  
Duration of treatment: Two menstrual cycles (1st 
day of the menstrual cycle).  
Anupana: Water  
Follow up: for the 5th day of the next menstrual cycle  
Group B 
Kumaryasava: 48ml  
Time of administration: orally 24ml twice daily 
after food.  
Duration of treatment: Two menstrual cycles (1st 
day of menstrual cycles)  
Follow up: For 5th day the next menstrual cycle 
Diagnostic Criteria 
The diagnosis was mainly based on, clinical 
presentation of the patient i.e., 
 The pain begins a few hours before or just with 
the onset of menstruation. 
 The pain is spasmodic and confined to lower 
abdomen. 
 Systemic discomforts like nausea, vomiting, 
fatigue etc., may be associated. 
Assessment Criteria 
Subjective parameters like pain, associated 
complaints and objective parameters like, menstrual 
bleeding were assessed based upon the scoring. 
Assessment scoring 
Assessment of pain during menstruation 
1) Intensity Grade 
Normal : 0   
Mild : 1 
Moderate : 2 
Severe  : 3 
2) Duration of Pain 
Absent   : 0 
Pain for one day few hours  : 1 
Pain for whole day (one day)  : 2 
Pain for two days  : 3 
 3) Nature of pain Grade 
Absent   : 0 
Occasional : 1 
Dull : 2 
Intermittent spasmodic : 3 
4) IMP  
21 to 35 days : 0 
<21 : 1 
>35 : 2 
5) Amount  
Scanty : 3- Spotting 
Average : 2 - 1 - 2 pads 
Normal : 1 - 3 - 4 pads 
Excessive : 0 - 5 or more 
6) Associated Complaints Total 10 complaints 
7-10 complaints : 3 
4- 6 complaints : 2 
1 -3 complaints : 1 
0 complaints : 0 
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7) Over all Assessment of therapeutic effect 
Cured : More than 75% 
Marked improvement : 51-74% 
Moderate 
improvement 
: 26-50% 
Mild improvement : Less than 25% 
Observation 
In the present study, the subjective and 
objective parameters were observed, analysed and 
interpreted to prove the efficacy of the drugs 
recommended in the study groups. First the socio 
demographic characteristics such as age, domicile, 
occupation, socio-economic status, educational 
status, religion were taken for assessing the equality 
of both the groups. 
 Data related to Kashtartava were thoroughly 
evaluated and interpreted. The conditions such as 
pattern of menstrual bleeding, painful menstruation 
were also assessed.  
 Data regarding personal history of both 
groups like occupation, diet were also collected. Age 
of marriage, contraceptive history, family history, 
parity etc., was also taken into consideration as these 
are thought to be affecting the disease indirectly.  
The data collected were classified as follows.  
Section A: Data related to socio demographic 
background  
Section B: Data related to personal history  
Section C: Data related to clinical study 
Section A: Data Related To Socio Demographic Background 
Table 1: Distribution of patient according to Age 
Age Group A Group B Total Percentage 
15-20 5 8 13 43.3% 
21-25 0 7 17 56.6% 
Among 30 patients, 43.3% in 15-20yrs of age group, 56.6% in 21-25yrs of age group. 
Graph No 1 
 
Table 2: Distribution of patients according to Domicile 
Domicile Group A Group B Total Percentage 
Urban 6 7 13 43% 
Rural 9 8 17 57% 
Among 30 patients, 43% belongs to urban area. 57% belongs to rural area. 
Graph No 2 
 
Table 3: Incidence according to marital status 
Marital status Group A Group B Total Percentage 
Married 6 7 13 43% 
Unmarried 9 8 17 57% 
Among 30 patients, 43% were married. 57% were unmarried. 
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Graph No 3 
 
Table 4: Distribution of patients according to occupation 
Occupation Group A Group B Total Percentage 
Service 2 4 6 20% 
Labor 4 5 9 30% 
Student 9 6 15 50% 
Among 30 patients, 20% were Service, 30% were Labor, 50% Students. 
Graph no 4 
 
Table 5: Distribution of patients According Socioeconomic Status 
Socio economic 
Status 
Group A Group B Total Percentage 
Lower class 3 2 5 16.7% 
Middle class 7 6 13 43.3% 
Upper class 5 7 12  40% 
Among 30 patients, 43.3 % patients were belonging to middle class, 40% were from lower class and 16.7% 
were belonging to upper class. 
Graph no 5 
 
Section B: Data Related to Personal History 
Table 6: Distribution of patients according to diet 
Diet Group A Group B Total Percentage 
Veg 4 3 7 23% 
Mixed 11 12 23 77% 
Among 30 patients, 23% were Vegetarian, 77% were taken mixed. 
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Graph no 6 
 
Table 7: Distribution of patients according to Prakruti 
Prakruti Group A Group B Total Percentage 
Vatakapha 7 5 12 40% 
Kapha Pitta 2 2 4 13.3% 
Pitta Kapha 1 1 2 6.7% 
Kapha Vata 1 1 2 6.7% 
Vata Pitta 4 6 10 33.3% 
Among 30 patients, majority were of Vatakapha Prakriti with 40%. 33.3% were of Vatapitta Prakriti and 6.7 % 
were of Pittakapha Prakriti, Kaphapittaprakriti were 13.3%, Kaphavata were 6.7%. 
Graph No 7 
 
Table 8: Distribution of patients according to Parity 
Parity Group A Group B total Percentage 
P0 14 14 28 93.3% 
P1 1 1 2 6.6% 
P2 0 0 0 0 
Among 30 patients, Majority of patients were having no children i.e., 93.3% and 6.6% patients were having one 
child. 
Graph no 8 
 
Table 9: Distribution of patients according to Family history 
Family History Group A Group B Total Percentage 
Absent 12 14 26 86% 
Present 3 1 4 13.3% 
0
5
10
15
20
25
Veg Mixed
Group A
Group B
Total
0
2
4
6
8
10
12
14
VataKapha KaphaPitta PittaKapha KaphaVata Vatapitta
Group A
Group B
Total
0
10
20
30
Parity 0 Parity1 Parity 2
Group A
Group B
Total
Int. J. Ayur. Pharma Research, 2018;6(10):26-40 
     Available online at: http://ijapr.in  32 
Among 30 patients, 93.3% were not shown any family history. 13.3% of patients had family history. 
Graph No 9 
 
Table 10: Distribution of patients according to Mental Stress 
Mental Stress Group A Group B Total Percentage 
Present 10 7 17 56.67% 
Absent 5 8 13 43.33% 
Among 30 patients, 56.67% patients had mental stress, in 43.33% patient it was absent.  
Graph no 10 
 
Table 11: Distribution of patients according to Satva 
Satva Group A Group B Total Percentage 
Pravara 0 0 0 0% 
Madhyama 14 14 28 93.3% 
Avara 1 1 2 6.6% 
Among 30 patients, 93.3% were Madhyamasatva, 6.6% were Avarasatva. 
Graph no 11 
 
Table 12: Distribution of patients according to Samhanana 
Samhanana Group A Group B Total Percentage 
Pravara 0 0 0 0 
Madhyama 13 15 28 93% 
Avara 2 0 2 6.6% 
Among 30 patients, 93% were Madhayama samhanana, 6.6% were Avara. 
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Graph no 12 
 
Table 13: Distribution of patients according to Pramana 
Pramana Group A Group B Total Percentage 
Pravara 0 0 0 0 
Madhyama 15 15 30 100% 
Avara 0 0 0 0 
Among 30 patients,100% Patients had Madhyama Pramana. 
Graph no 13 
 
Table 14: Distribution of patients according to Vyayama Shakti 
Vyayama shakti Group A Group B Total Percentage 
Pravara o 0 0 0 
Madhyama 15 14 29 96.67% 
Avara 0 1 1 3.33% 
Among 30 patients, 96.67% patients had Madhyamavyayama Shakti and 3.33% had Avaravyayama Shakti. 
Graph no.14 
 
Table 15: Distribution according to Ahara Shakti 
Ahara Shakti Group A Group B Total Percentage 
Pravara 0 0 0 0 
Madhyam 9 8 17 56.67% 
Avara 6 7 13 43.33% 
Among 30 patients, 56.67% patients had Madhyamaahara Shakti and 43.33% had Avaraahara Shakti. 
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Graph no 15 
 
Section C-Chief Complaints 
Table 16: Distribution of patients according to Intensity of pain 
Location of Pain Group A Group B Total Percentage 
Mild 10 11 21 70% 
Moderate 03 04 07 23.3% 
Severe 01 01 2 6.6% 
Among 30 Patients, 70% had Mild pain. 23.3% had Moderate pain 6.6% had severe pain 
Table 17: Distribution of patients according to duration of pain 
Duration (In days) Group A Group B Total Percentage 
1-2 7 7 14 46.67% 
3-4 6 7 13 43.33% 
5-6 2 1 3 10% 
Among 30 Patients, 46.67% patients had 1-2 days pain, 43.33% patients had 3-4 days pain and 10% had 5-6 
days pain. 
Graph no 17 
 
Table 18: Distribution of patients according to Nature of Pain 
Nature of Pain Group A Group B Total Percentage 
Spasmodic 7 8 15 50% 
Dull 1 0 1 3.3% 
Continuous 8 6 14 46.6% 
Intermittent 0 0 0 0 
Among 30 Patients, 50% had spasmodic pain. 3.3% had dull pain. 46.6% had continuous pain. 
Graph no 18 
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Table 19: Distribution of patients according to amount of menstrual bleeding 
Amount of Bleeding Group A Group B Total Percentage 
Normal 10 8 18 6o% 
Scanty 6 6 12 40% 
Among 30 Patients, 60% had minimal bleeding. 40% had Scanty (Spotting) bleeding.. 
Graph no 19 
 
Table 20: Distribution of patients according to Duration of bleeding 
Duration Group A Group B Total Percentage 
1-2days 05 06  11 36% 
3-4 days 7 7 14 46% 
5-6 days 3 2 5 16% 
Among 30 Patients, 36% had duration of bleeding up to 1-2days, 46. % had 3-4days, 46.% had 5 to 6 days. 
Graph 20 
 
Table 21: Distribution of patients according to Associated Complaints 
Complaints Group A Group B Total Percentage 
Nausea 5 6 11 36.67 
Vomiting 8 9 17 56.67 
Fatigue 11 12 23 76.67 
Constipation 6 7 13 43.33 
Head ache 4 5 9 30 
Sweat 3 2 5 16.67 
Vaginal discharge 2 0 2 10% 
Among 30 Patients, 36.67% patients had nausea, 56.67% had vomiting, 76.67% had fatigue, 43.33% had 
constipation, 30% had headache, 16.67% had sweating, 10% vaginal discharge. 
Graph 21 
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RESULT 
Effect of treatment 
Table 22: Group A: Intensity of Pain 
Mean Mean % M.D t Test 
BT AT SD SE t P 
AT1 2.067 1.133 45% 0.933 0.2582 0.0666 14.00 <0.001 
AT2 2.067 0.333 64% 1.333 0.7238 0.1869 7.135 <0.001 
AT3 2.067 0.133 94% 1.933 0.5936 0.1533 12.614 <0.001 
The mean score of the symptom which was 2.067 before treatment reduced to1.13 with mean difference of 
0.93±0.0.25 after treatment on 30th day and reduced to 0.33 with mean difference of1.33±0.72 after treatment 
on 60th day and further reduced to 0.13 with mean difference of 1.53≠0.59 on follow up. 
Table 23: Group B: Intensity of Pain 
Mean Mean AT  % M D t TEST 
 BT AT   SD SE t P 
AT1 1.800 1.200 33% 0.600 0.6325 0.1633 3.674 <0.001 
AT2 1.800 0.800  55% 1.000 0.6761 0.2182 4.458 <0.001 
AT3 1.800 0.600 66% 1.200 0.1447 8.290 6.261 <0.001 
The mean score of the symptom which was 1.8 before treatment reduced to 1.2 with mean difference of 0.6 ± 
0.63 after treatment on 30th day and reduced to 0.8 with mean difference of 1.2±0.67 after treatment on 60th 
day and further reduced to 0.6 with mean difference of 1.2±0.14 on follow-up. 
Table 24: Duration of pain in the Group A  
Mean  Mean  % M D t TEST 
 BT AT   SD t p 
AT1 1.867 1.133 39% 0.733 0.4577 0.1182 6.205 
AT2 1.867 0.625  64% 1.200 0.7746 0.2000 6.000 
AT3 1.867 0.200 89% 1.667 0.8997 0.2333 7.174 
The mean score of the symptom which was 1.86 before treatment, reduced to 1.13 with mean difference of 
0.73±0.45 after treatment on 30th day and reduced to 0.6 with mean difference of 1.2±0.77 after treatment on 
60th day and further reduced to 0.2 with mean difference of 1.6±0.8 on follow up. 
Table 25: Duration of pain in Group B  
Mean  Mean  % M D t TEST 
 BT AT   SD SE t P 
AT1 1.800 1.133 37% 0.667 0.4880 0.1260 5.292 <0.001 
AT2 1.800 0.7333 59% 1.067 0.7037 0.1817 5.870 <0.001 
AT3 1.800 0.4000 77% 1.400 0.9856 0.2545 5.501 <0.001 
The mean score of the symptom which was 1.8 before treatment reduced to 1.13 with mean difference of 
0.6±0.48 after treatment on 30th day and reduced to 0.73 with mean difference of 1.067±0.70 after treatment 
on 60th day and further reduced to 0.4 with mean difference of 1.4±0.98 on follow up. 
Table 26: Nature of pain in Group A  
Mean  Mean AT  % M D t TEST 
 BT AT   SD SE t P 
AT1 1.600 1.067 33 0.5333 0.7432 0.1919 2.779 <0.01 
AT2 1.600 0.4667 70 1.133 1.302 0.3362 3.371 <0.01 
AT3 1.600 0.2000 87 1.400 1.352 0.3491 4.010 <0.01 
The mean score of the symptom which was 1.6 before treatment reduced to 1.06 with mean difference of 
0.53±0.74 after treatment on 30th day and reduced to 0.4 with mean difference of 1.13±1.13 after treatment on 
60th day and further reduced to 0.2 with mean difference of 1.4±1.3 on follow up. 
Table 27: Nature of pain in Group B  
Mean  Mean AT  % M D t Test 
 BT AT   SD SE t P 
AT1 1.267 0.7333 41 0.5333 0.5164 0.1333 4.000 <0.01 
AT2 1.267 0.4667 66 0.8000 0.6761 0.1746 4.583 <0.001 
AT3 1.267 0.0666 75 0.0900 0.8619 0.2225 5.392 <0.001 
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The mean score of the symptom which was 1.2 before treatment reduced to 0.7 with mean difference of 
0.53±0.51 after treatment on 30th day and reduced to 0.8 with mean difference of 1.2±0.67 after treatment on 
60th day and further reduced to 0.06 with mean difference of 0.090±0.86 on follow up. 
Table 28: Amount of bleeding in Group A Table no 7 
Mean  Mean  % M D t TEST 
 BT AT   SD SE t P 
AT1 1.200 0.667 44 0.5333 0.5164 0.1333 4.000 <0.01 
AT2 1.200 0.200 83 1.000 0.8452 0.2182 4.583 <0.001 
AT3 1.200 0.066 94 1.`133 0.9904 0.2557 4.432 <0.001 
The mean score of the symptom which was 1.2 before treatment reduced to 0.6 with mean difference of 
0.5±0.51 after treatment on 30th day and reduced to 0.2 with mean difference of 1.0±0.84 after treatment on 
60th day and further reduced to 0.06 with mean difference of 1.13±0.99 on follow up. 
Table 29: Amount of blood in Group B  
Mean  Mean A % M D t TEST 
 BT AT   SD SE T P 
AT1 1.533 0.6000 26 0.400 0.6325 0.1633 2.449 <0.01 
AT2 1.533 0.6000 60 0.933 0.4577 0.1182 7.897 <0.001 
AT3 1.533 0.0666 64 0..967 0.6399 0.1652 8.876 <0.001 
The mean score of the symptom which was 1.5 before treatment reduced to 0.6 with mean difference of 
0.6±0.40 after treatment on 30th day and reduced to 0.6 with mean difference of 0.9±0.45 after treatment on 
60th day and further reduced to 0.6 with mean difference of 0.9±0.96 on follow up. 
Table 30: Intra menstrual period Group A  
Mean B Mean AT  % M D T test 
 BT AT   SD SE T P 
AT1 1.600 0.8667 45 0.7333 0.5936 0.1533 4.785 <0.001 
AT2 1.600 0.6000 62 1.000 0.8452 0.2182 4.583 <0.001 
AT3 1.600 0.4000 75 1.200 0.9411 0.2430 4.938 <0.001 
The mean score of the symptom which was 1.6 before treatment, reduced to 0.86 with mean difference of 
0.73±0.59 after treatment on 30th day and reduced to 0.60 with mean difference of 1.0±0.84 after treatment on 
60th day and further reduced to 0.4 with mean difference of 1.2±0.94 on follow-up.. 
Table 31: Intra menstrual period Group B  
Mean  Mean  % M D T Test 
 BT AT   SD SE T P 
AT1 1.600 0.7333 28 0.3333 0.4880 0.1260 2.646 <0.01 
AT2 1.600 0.6667 37 0.4000 0.6325 0.1633 2.449 <0.01 
AT3 1.600 0.5333 47 0.5333 0.6399 0.1652 3.228 <0.01 
The mean score of the symptom which was 1.06 before treatment, reduced to 0.7with mean difference of 
0.33±0.48 after treatment on 30th day and reduced to 0.6 with mean difference of 0.40±0.63 after treatment on 
60th day and further reduced to 0.5 with mean difference of 0.53±0.63 on follow-up. 
Table 32: Associated Complaints in Group A  
Mean  Mean AT  % M D t Test 
df BT AT   SD SE t P 
14 1.267 0.6667 50 0.6000 0.5071 0.1309 4.583 <0.001 
14 1.267 0.1333 86 1.033 0.9155 0.2364 4.795 <0.001 
14 1.267 0.2000 88 1.067 1.100 0.2840 3.756 <0.01 
The mean score of the symptom which was 1.2 before treatment, reduced to 0.6 with mean difference of 
0.60±0.50 after treatment on 30th day and reduced to 0.13 with mean difference of 1.03±0.91 after treatment 
on 60th day and increased to 0.20 with mean difference of 1.067±1.06 on follow up. 
Table 33: Associated Complaints in Group B  
Mean  Mean AT  % M D  t Test 
 BT AT   SD SE t P 
AT1 1.067 0.6667 37 0.4000 0.5071 0.1309 3.055 <0.01 
AT2 1.067 0.2667 75 0.8000 0.8619 0.2225 3.595 <0.01 
AT3 1.067 0.1333 84 0.9333 1.033 0.2667 3.500 <0.01 
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The mean score of the symptom which was 1.06 before treatment, reduced to 0.6 with mean difference of 
0.40±0.50 after treatment on 30th day and reduced to 0.26 with mean difference of 0.80±0.86 after treatment 
on 60th day and further reduced to 0.13 with mean difference of 0.93±0.1.03 on follow up. 
 Table 34: Comparative Effect of Group A and Group B 
Signs and Symptoms  Mean Difference % of Relief  T Value P value 
Group A Group B Group A Group B 
Intensity of pain 0.933 1.133 94 66 3.550 < 0.01  
Duration of pain  1.600 1.400 89 77 0.577 > 0.05  
Nature of pain 1.200 1.067 87 75 0.464 > 0.05  
Amount of blood 0.8667 1.333 94 64 1.742 >0.05 
Intramenstrual period 1.200 0.5333 75 47 2.269 <0.05 
Associated complaints 1.067 0.800 88 84 0.739 > 0.05  
Table 35: Showing overall effect of treatment on group A and Group B 
Effect of Therapy Group A % Group B % 
Cured 100% relief  4 26 2 13 
Markedly improved ≥75%  6 40 9 60 
Moderately improved 50 -74% relief  4 25 2 13 
Graph no: 22 showing overall effect of treatment on group A and group B 
In Group A, 4 patients (26 %) were completely cured, 6 patients (40 %) were markedly improved, 4 
patients (25%) were moderately improved and one patient (6 %) was partially improved.  
In Group B 2 patients (13 %) were completely cured, 9 patients (60 %) were markedly improved, 2 
patients (13.3 %) were moderately improved, 2 patients (13.3 %) were partially improved. 
DISCUSSION ON RESULTS 
Effect of treatment was clinically assessed 
before after treatment and on follow up. 
Effect of treatment on Intensity of pain during 
M.C. 
Among 15 patients in trial group 6 were 
having severe pain 9 were having moderate pain. 
Among 15 patients in control group 7 were having 
severe pain 8 were having moderate pain.  
The mean score of the symptom which was 
2.06 before treatment, reduced to 0.13 after 
treatment in trial group. In control group it has 
decreased from 1.80 to 0.60 after treatment. 
Statistical analysis of the difference observed 
between the two groups proved to be significant 
(P<0.01).  
In trial group, 94% relief was observed and 
results were highly significant statistically (<0.001). 
Effect of treatment on duration of pain  
Among 15 patients in trial group 10 were 
having pain premenstrual 4 to 5 days. 5 patients 
were having pain during menstruation 3 days. Among 
15 patients in control group 7 were having pain 
premenstrual 4 to 5 days. 8 were having pain during 
menstruation for 3to 4 days. 
The mean score of the symptom which was 
1.86 before treatment, reduced to 0.20 after 
treatment in trial group. In control group it has 
decreased from 1.80 to 0.40 after treatment. 
Statically analysis of the difference observed between 
the two groups proved to be insignificant (P>0.05). In 
trial group, 89% relief was observed and results were 
highly significant statistically (<0.001). Rutukarivati 
having Shunti, Hingu, Haridra dravyas acts as 
Vatashamak (Apanavata).  
Effect of treatment on Nature of pain 
Among 15 patients in trial group, 6 were 
having spasmodic pain, 5 were having dull pain and 4 
having continuous pain. Among 15 patients in control 
group, 9 were having spasmodic pain. 4 were having 
intermittent pain, 2 were having dull pain. 
 The mean score of the symptom which was 
1.60 before treatment, reduced to 0.20 after 
treatment in trial group. In control group it has 
decreased from 1.20 to 0.06 after treatment. 
Statically analysis of the difference observed between 
the two groups proved to be insignificant (P>0.05). In 
trial group, 87% relief was observed and results were 
highly significant statistically (<0.001). May be study 
of drugs contain Kumari, Haridra are Antiprogladin 
and antisposomodic activity. 
Effect of treatment on Intramenstrual period 
Among 15 patients in trial group, 6 were 
having irregular cycle. Among 15 patients in control 
group 9 were having ½ days menstrual flow. 6 were 
having ¾ days menstrual flow.  
The mean score of the symptom which was 
1.60 before treatment reduced, 0.40 after treatment 
in trial group. The mean score of the symptom of 
which was 1.067 before treatment reduced to 0.53 
after treatment in control group. Statically analysis of 
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the difference observed between the two groups 
proved to be insignificant (P>0.05). In trial group, 
75% relief was observed and results were highly 
significant statistically (<0.001). Dravyas are like 
Hingu, Tankana[15], Hariidra, kumara are having the 
property of Artavajanana property. 
Effect of treatment on Menstrual flow (Amount of 
blood loss) 
Among 15 patients in trial group 12 were 
having ½ days menstrual flow Scanty.3 were having 
3/4 days mf. Among 15 patients in control group 9 
were having 1/2days menstrual flow, 6 were having 
¾ days menstrual flow.  
The mean score of the symptom of which was 
1.20 before treatment reduced 0.06 after treatment 
in trial group. The mean score of the symptom of 
which was 1.53 before treatment reduced to 0.06 
after treatment in control group. Statically analysis of 
the difference observed between the two groups 
proved to be insignificant (P>0.05).  
In trial group, 94% relief was observed and 
results were highly significant statistically (<0.001). 
May be Dravyas having the properties of Katu Vipaka, 
Ushna Virya, Tikshna, Sara guna increased the 
menstrual flow. 
Effect of treatment on associated complaints 
Among 15 patients in trial group, 12 were 
having 3 complaints. 3 were having no complaints. 
Among 15 patients in control group 9 were having 3 
complaints 5 were having 2 complaints, 1 was having 
6 complaints. 
The mean score of the symptom of which was 
1.200 before treatment reduced to 0.2 after 
treatment in trial group. The mean score of the 
symptom of which was 1.06 before treatment 
reduced to 0.13 after treatment in control group. 
Statically analysis of the difference observed between 
the two groups proved to be insignificant (P>0.05).  
In trial group, 94% relief was observed and 
results were highly significant statistically (<0.001) 
maybe Dravyasgunaprabhava (Tiksna, Sara, Laghu) 
and Rasa (Tikta, Kasaya, Laghu) decreases the 
Kaphapitta. 
Overall assessment of therapeutic effect 
In Group A, 4 patients (26%) were completely 
cured, 6 patients (40%) were markedly improved, 4 
patients (25%) were moderately improved and 1 
patient (6 %) was partially improved.  
In Group B 2patients (13%) were completely 
cured, 9 patients (60%) were markedly improved, 2 
patients (13.3%) were moderately improved, 2 
patients (13.3%) was partially improved. 
 
 
CONCLUSION 
 Dysmenorrhoea, which means painful 
menstruation, is frankly not a disease. It is 
symptom associated with much gynaecological 
pathologies. But when it present solely as a 
compliant association of any other symptom, it 
may be considered as a primary dysmenorrhoea. 
 In the classics of Ayurveda, painful menstruation 
finds its role as a sole symptom in Udavartha 
Yoniyapat, as well as associated complaint with 
many other symptoms in the cases of 
Vatajyonivyapat, Vatajarthavadrusti, Pariplutha 
yoni yapath. 
 In disease Kashtartava there is mainly 
derangement of Vata dosha. The reasons for Vata 
vitiation are Margavarodha, Dhatukshaya and 
Swanidana Prakopa. Margavarodha i.e., 
obstruction either physiological or anatomical. 
 As in all cases of Kashtartava Vata Prakopa is the 
main factor, the treatment should be directed to 
the treatment of Vata and its cause. For Avrita 
Apana Vayu, the treatment should be 
Agnideepaka, Grahi, Vata Anulomaka and 
Pakvashayashuddhikara. 
 Produce the specific target action on the 
Garbhashaya, Arthava Dhatu and Apanavata; in 
which Kapha pitta shamaka property clears the 
Artavavaha Srotas and Ushnaguna and Veerya 
pacifies Apana Vata which in turn plays 
Vatanulomana. Dravyaprabhava of formulation 
helps in the process of cyclical healthy production 
of menstrual blood which is termed as 
Artavajanana in Ayurvedic Classics.  
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